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Abstract
To counter the global threat caused by Plasmodium falciparum malaria, new drugs and vaccines are urgently needed.
However, there are no practical animal models because P. falciparum infects human erythrocytes almost exclusively. Here
we describe a reliable falciparum murine model of malaria by generating strains of P. falciparum in vivo that can infect
immunodeficient mice engrafted with human erythrocytes. We infected NODscid/b2m2/2 mice engrafted with human
erythrocytes with P. falciparum obtained from in vitro cultures. After apparent clearance, we obtained isolates of P.
falciparum able to grow in peripheral blood of engrafted NODscid/b2m2/2 mice. Of the isolates obtained, we expanded in vivo
and established the isolate Pf3D70087/N9 as a reference strain for model development. Pf3D70087/N9 caused productive
persistent infections in 100% of engrafted mice infected intravenously. The infection caused a relative anemia due to
selective elimination of human erythrocytes by a mechanism dependent on parasite density in peripheral blood. Using this
model, we implemented and validated a reproducible assay of antimalarial activity useful for drug discovery. Thus, our
results demonstrate that P. falciparum contains clones able to grow reproducibly in mice engrafted with human
erythrocytes without the use of myeloablative methods.
Citation: Angulo-Barturen I, Jime´nez-Dı´az MB, Mulet T, Rullas J, Herreros E, et al. (2008) A Murine Model of falciparum-Malaria by In Vivo Selection of Competent
Strains in Non-Myelodepleted Mice Engrafted with Human Erythrocytes. PLoS ONE 3(5): e2252. doi:10.1371/journal.pone.0002252
Editor: Jennifer Keiser, Swiss Tropical Institute, Switzerland
Received January 25, 2008; Accepted April 2, 2008; Published May 21, 2008
Copyright:  2008 Angulo-Barturen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Marı´a Bele´n Jime´nez-Dı´az, Teresa Mulet and Joaquı´n Rullas were funded by Medicines for Malaria Venture Miniportfolio Agreement with
GlaxoSmithKline-Diseases of the Developing World.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: inigo.x.angulo@gsk.com
Introduction
The erythrocytic stages of the most virulent human malaria
parasite, P. falciparum, are responsible for hundreds of millions of
illnesses and over one million deaths every year [1]. Due to its
exquisite specificity, only human beings and a small number of
non-human primates are susceptible to infection by the erythro-
cytic stages of P. falciparum [2]. The lack of available animals, high
costs and overt ethical problems have precluded the widespread
use of primates in malaria research. As an alternative, rodent or
avian plasmodial species non pathogenic for humans have been
used as surrogates of P. falciparum [3]. However, in spite of their
value, there are significant biological differences between these
species and the human parasite [4,5].
A reliable murine model of P. falciparum malaria would be a
valuable research tool, particularly in drug discovery [6]. At least,
such a model should guarantee that the parasite grows in a
predictable way in peripheral blood of mice having circulating
human erythrocytes (hE) in bloodstream, the physiologically
relevant compartment. This requires the availability of susceptible
hE, the competence of P. falciparum to grow using the nutrients
available and the ability of P. falciparum to overcome the innate
immune system of mice engrafted with human erythrocytes
(humanized mice, HM). So far, hE have been successfully grafted
into nude or scid immunodeficient mice upon intraperitoneal
injection using [7–11] or not [12] immunosuppressive treatments.
However, obtaining sustained infections with P. falciparum in HM
has only been possible by depleting in vivo tissular macrophages
and neutrophils with dichloromethylene diphosphonate-contain-
ing liposomes plus anti-neutrophil NIMP-R14 mAb [8–11,13].
Unfortunately, the different versions of this model require
intraperitoneal infection, have a high rate of failure [8,9,13] or
show limited reproducibility of infection outcome [10,11], display
variable kinetics of parasitemia, and use toxic reagents, which
might interact in unknown ways with antimalarials or effector
cells. These shortcomings have limited its use in drug discovery [3]
and vaccine development, despite several standard antimalarials
[9] and antibodies [13–15] were shown to have activity in this
model.
In order to develop a falciparum murine model useful for drug
discovery, we hypothesized that laboratory or clinical strains of P.
falciparum should contain clones able to survive and be expanded in
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vivo in non-myelodepleted HM. Supporting this hypothesis, firstly,
P. falciparum 3D7 adapted to grow in vitro in cultures containing
murine ascites could replicate intraperitoneally in NODscid HM
boosted daily with hE even though parasitemias in peripheral
blood were erratic and parasites were readily cleared from mice
[12,16]. Secondly, phagocyte-depleted HM are metabolically
permissive for P. falciparum laboratory and clinical isolates [9,11].
Finally, P. falciparum can evade host’s innate immune system in
natural infections by antigenic variation through expression of
alternative genes of multigene families [17,18]. Here we describe
the first murine model of falciparum malaria after intravenous
infection of non-myelodepleted humanized NODscid/b2m2/2 mice
with Pf3D70087/N9, to our knowledge the first strain of P. falciparum
generated specifically for a murine model, and demonstrate its
value as a reliable tool for drug discovery.
Results
Selection of the immunodeficient murine strain
The innate immunity of immunodeficient scid and nude mice is
able to reject xenotranplants [19] and eradicate parasites [20]. We
tested five immunodeficient murine strains for engraftment of A+
hE: NIH-IIIbeige/xid/nude, CB17scid, NODscid, which have already
been shown to be able to accept hE [7,9,12]; CB17scid/beige, which
has no NK activity [21,22] and NODscid/b2m2/2, which is one of
the best acceptors of human xenotransplants [23,24]. We
administered 1 ml of hE A+ 50% hematocrit 25% human serum
3.1 mM hypoxanthine in RPMI 1640 daily by i.p. to maximize
the volume of suspension injected and obtain a sustained delivery
of erythrocytes to the vascular system, likely through lymphatic
drainage [12]. The hE suspension contained human serum and
hypoxanthine because human serum increases the half life of
engrafted hE [7] and both components might enhance the growth
of P. falciparum. We injected four mice of each strain daily with hE
and measured the degree of engraftment over 15 days (Fig. 1).
Consistently with previous reports [9,10], NIH-IIIbeige/xid/nude mice
were almost refractory to engraftment. Conversely, CB17scid/beige,
CB17scid, NODscid, and NODscid/b2m2/2 mice were engrafted
fitting a one phase exponential association equation, with CB17scid,
NODscid and NODscid/b2m2/2 showing the best engraftment
(Fig. 1). Finally, we selected NOD background mice for further
experiments because those mice have defects in serum comple-
ment, NK cell activity and macrophage activation whereas these
components are intact in CB17 mice [25].
Selection of a competent P. falciparum 3D7 strain
We hypothesized that some clones of P. falciparum could survive
in peripheral blood of HM without using chemical phagocyte
depletion. Although cultured in vitro for decades, we selected P.
falciparum 3D7 because it was the one used by Moore et al [12], it is
well characterized and still is the most widely used for in vitro drug
testing. Then, we infected 10 NODscid and NODscid/b2m2/2 HM
having 40–50% of chimerism (7–9 days after starting i.p. injections
of hE) with i.p. injections of 1 ml 50% hematocrit with
approximately 2% of parasitemia because the i.p. route was the
only route for which successful infections were obtained previously
[9,12,13,26] (Fig. 2, A). Similarly to Moore et al. [12], after some
initial replication, all NODscid mice cleared parasites from
peripheral blood. However, after apparent clearance, two
NODscid/b2m2/2 mice showed productive infections at days 26
and 30 after parasite inoculation (Fig. 2, B). The frequency of
successful infections in the experiments performed (3 different
experiments, n = 5, n = 10 and n = 12, respectively) was about 10–
20%. Therefore, P. falciparum 3D7 growing in vitro contained
parasites able to survive in NODscid/b2m2/2 HM not treated with
myelosuppressive drugs. This was not restricted to Plasmodium 3D7
and the i.p. route of infection because after i.p. or i.v. infection of
NODscid/b2m2/2 HM with P. falciparum V1/S (n = 10 mice), a
multiresistant clinical isolate adapted to in vitro culture, the
percentage of success was 100%. This confirmed that other strains
contain parasites competent to grow in NODscid/b2m2/2 HM
(Fig. 2, B).
Next, we demonstrated that surviving parasites could be
transmitted and expanded in vivo in NODscid/b2m2/2 HM, which
we selected for further experiments. We infected i.p. three HM per
donor with ,25?106 parasites obtained from two cohort 1 mice
having $1% parasitemia in peripheral blood (named isolates
Pf3D70087/N5 and Pf3D70087/N9). All mice were infected and
showed parasitemias between 0.1 and 8% for more than one
month, similarly to successful infections obtained by Moreno et al
[9]. As we obtained the same results in four sequential infections
using the first mice of each passage achieving parasitemias$1% as
donor for the next cohort, we concluded that both isolates could be
transmitted in vivo. The erratic parasitemias observed in mice could
be due to the growth of P. falciparum 3D7 that we observed in the
peritoneum of HM, as described in other models [12,26].
Interestingly, all mice inoculated i.v. with 206106 Pf3D70087/N5-
or Pf3D70087/N9-parasites showed productive infections. In all
cases, we obtained a reproducible exponential growth and
achieved parasitemias above 1% one week after infection for ten
consecutive i.v. passages in vivo (Fig. 2, C). Thus, we expanded
Pf3D70087/N5 and Pf3D70087/N9 isolates infecting 14 and 40 mice
by i.v. route with 20?106 parasites, respectively. The parasites grew
exponentially in all HM mice and we froze parasites one week
after infection for establishing parasite stock reference collections
for standardization. The isolates Pf3D70087/N5 and Pf3D70087/N9
had parasitemias at freezing of 2.760.15 and 2.2860.14%,
respectively.
Finally, we selected the strain Pf3D70087/N9 for full model
characterization. This strain produced a characteristic pattern of
nine bands after microsatellite PfRRM fingerprinting [27] whereas
Figure 1. Selection of immunodeficient mice. The percentage of
hE (TER-1192 or human glycophorin A+ cells) in peripheral blood of
NIH-IIIbeige/xid/nude, CB17scid, CB17scid/beige, NODscid and NODscid/b2m2/2
murine strains upon daily intraperitoneal injection of hE is shown. The
regression curves for fitting to an exponential association equation are
shown for CB17scid, CB17scid/beige, NODscid and NODscid/b2m2/2. The strain
NIH-IIIbeige/xid/nude was discarded from the study at the point indicated
(w). Data are the mean6SE of n = 4 mice per data point.
doi:10.1371/journal.pone.0002252.g001
P. falciparum in Mice
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the original P. falciparum 3D7 showed eleven DNA fragments, eight
of them identical to Pf3D70087/N9 (Fig. 2, D). Interestingly,
Pf3D70087/N9 grew in vitro as the parental P. falciparum 3D7
(duplication time ,1 day), either cultured from frozen stocks or
when taken directly from the peripheral blood of infected mice,
and maintained the parental pattern of susceptibility to control
antimalarial compounds (Table 1). In addition, Pf3D70087/N9 was
able to grow after i.v. infection in murine strains successfully
engrafted with hE (CB17scid and NODscid) (Fig. 2, E). Hence, the
procedure described above led to selection of a variant of P.
falciparum 3D7 competent to grow reproducibly in peripheral blood
of HM.
Long-term chimerization
Next, we analyzed the effects of long-term daily injections of hE
in NODscid/b2m2/2 mice. In practice, 100% of mice were
successfully grafted with hE. The acquisition of chimerism fitted
a one phase exponential association equation (R2 = 0.75, n = 162
mice, t1/2 = 7.560.6 days) reaching levels of .90% hE by day 25
(Fig. 3, A) irrespective of their ABO or Rh group (not shown).
The elimination of human serum from erythrocyte suspensions
slightly diminished the engraftment (chimerism-time AUC0R10
= 330.8621 days with serum versus 224.6676 days without serum,
n = 3 mice/group, P= 0.04, one tail unpaired t-test) (Fig. 3, A,
inset) whereas deprivation of exogenous hypoxanthine had no
effect (not shown). In addition, the pathological analysis of brain,
kidney, liver and spleen of HM showed vascular congestion and
elevated hematocrit (70.9611.6 in engrafted mice vs 46.560.9 in
non-conditioned NODscid/b2m2/2 mice) as the only relevant
findings (n = 6 mice?group21, 8 days after starting conditioning)
(Fig. 3, B). Consistently, the concentration of the circulating
erythrocytes was high (9.461.1,6109 E?ml21, n = 50 mice) (Fig. 3,
C). Noteworthy, although conditioned mice showed hepatomeg-
aly, mild splenomegaly and significant elevations in BUN,
bilirubin, and total protein (Table 2), we did not observe any
overt sign of disease in mice. Therefore, we could obtain a high,
reproducible and well-tolerated engraftment of hE for long periods
in the absence of cytoreductive therapies.
Dynamics of infection
Next, we studied the dynamics of infection in HM infected i.v.
with the established Pf3D70087/N9 strain. We infected a group of
mice (n = 3) having 40–50% circulating hE (7–10 days after
starting hE injections) with 20?106 Pf3D70087/N9-infected human
Figure 2. Optimized selection and characterization of competent P. falciparum isolates. (A) A cohort C1 of mice is conditioned for 7–10
days with daily i.p. injections of hE. Then, the mice are infected by i.p. or i.v. route with 25?106 or 50?106 parasitized erythrocytes from in vitro cultures.
Parasitemia in peripheral blood is followed up to 1 month after infection or until about 1% of parasitemia is achieved (see point B). Mice having
productive infections are used as donors to infect by i.v. route a cohort C2 of conditioned mice. After 1 week of infection, the mice with the highest
parasitemia is selected as donor for next in vivo passage. After ten passages showing a stable kinetics of growth (see point C), a final expansion step is
performed to establish a standard P. falciparum strain, which is frozen and used in experiments. (B). Course of parasitemia in peripheral blood from
the mice that originated the competent isolates Pf3D70087/N9 (i.p. infection), PfV1/S0176/N7 (i.p. infection) and PfV1/S0176/N10 (i.v. infection). (C) Dot plot
analysis of the kinetic stability of the isolate Pf3D70087/N9 growth during sequential i.v. infections with 20?106 P. falciparum-infected erythrocytes.
Stability in 10 sequential i.v. infections was used as the criterion for establishing the reference standard Pf3D70087/N9 strain. Each data point is the
mean of three mice per in vivo passage for ten consecutive passages. (D) Microsatellite PfRRM of the P. falciparum 3D7 and Pf3D70087/N9 strains. (E)
Growth of Pf3D70087/N9 in different strains of HM after i.v. infection with 20?106 Pf3D70087/N9 parasites. Data are the mean6SE of four mice?group21.
doi:10.1371/journal.pone.0002252.g002
P. falciparum in Mice
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erythrocytes (ihE) and measured the concentration of ihE, murine
erythrocytes (mE) and hE in peripheral blood of mice up to 36
days after infection. As shown in Fig. 4, A and in Table 3, the
infection with Pf3D70087/N9 followed a characteristic pattern and
consistently changed the dynamics of hE and mE in peripheral
blood of mice (three independent experiments, with n = 3, 4, and 3
mice, respectively). The growth of Pf3D70087/N9 in peripheral
blood of HM was associated with a severe decrease in total
erythrocyte concentration with respect to uninfected HM (up to
50% of reduction) explained by the selective elimination of hE
from peripheral blood of infected mice, which induced a
compensatory increase in circulating mE. The treatment of
infected HM with a suboptimal dose of chloroquine (10 mg?Kg21,
once a day for 4 days, p.o.) reduced the parasite burden and
eliminated the loss of hE while the number of mE dropped
continuously as in uninfected chimeric mice. Of note, recrudescent
parasites grew exponentially as after initial infection. Thus, our
results indicate that a high density of P. falciparum triggers the
elimination of hE, which is associated with a severe impairment of
parasite growth in which the spleen seemed to be involved. In
mice, the spleen is a key organ for elimination of senescent
erythrocytes [28] and ihE upon recruitment of phagocytes [26].
Interestingly, splenectomy showed negligible effects in chimerism
or parasitemia during the exponential growth of the parasite, but
improved chimerism (P= 0.032, Student’s t test, n = 6 mi-
ce?group21) and parasitemia (P= 0.009, Student’s t test, non
homogeneous variance, n = 6 mice?group21) only when this latter
reached a plateau or started to decrease (Fig. 4, C).
Therefore, Pf3D70087/N9 injected i.v. was able to produce
sustained and reproducible infections in HM. Moreover, the
growth of the parasite caused a relative anemia due to selective
elimination of hE by mechanisms dependent on the density of
parasites in peripheral blood.
Characterization and validation of a standardized assay
for antimalarial efficacy
We develop a standardized in vivo assay useful for drug discovery
to demonstrate the usefulness of the murine falciparum malaria
model. The first 10 days after infection encompassed up to five
parasitic cycles of 48 h and in this period, the parasite density was
low enough to allow a reproducible exponential growth of
Pf3D70087/N9 up to the maximum parasitemia. All HM infected
i.v. with 20?106 Pf3D70087/N9-ihE showed a one-phase exponential
association function kinetics of parasitemia up to day 7 after
Table 1. Comparison of the activity of selected antimalarials
against P. falciparum 3D7 or Pf3D70087/N9 1.
Compound P. falcipaum strain
3D7 Pf3D70087/N9
Artesunate 1,160,42 1,360,4
Chloroquine 16,260,5 11,163,6
Artemisinin 4,161,5 4,960,7
Pyrimethamine 4,660,8 3,960,8
Atovaquone 0,260,07 0,360,09
1The activity of antimalarials is expressed as the concentration in ng?ml21 that
inhibits by 50% the incorporation of [3H]-hypoxanthine (IC50).
2Differences between IC50 were not statistically significant in any case.
doi:10.1371/journal.pone.0002252.t001
Figure 3. Engraftment of hE in NODscid/b2m2/2. (A) Long term kinetics of engraftment of NODscid b2m2/2 mice with hE. Data are the mean
percentage6SE of hE (TER-1192 or human glycophorin-A+ mouse) erythrocytes pooled from 142 mice. The inset plot shows the effect of human
serum deprivation from daily-inoculated hE on engraftment of hE in peripheral blood of NODscid b2m2/2 (n = 3 mice?group21). Data shown are from a
representative experiment out of three. (B) Histological analysis of brain, kidney, liver and spleen of NODscid/b2m2/2 control, conditioned with hE and
conditioned mice infected with P. falciparum (day 8 after infection). Non-infected mice conditioned with hE showed a marked vascular congestion
compared to control mice. Infected mice, showed decreased vascular congestion, increased numbers of myelomonocytic cells and enhanced
phagocytic activity in the spleen (6600 magnification). (C) Concentration of erythrocytes, hE and mE in peripheral blood of NODscid b2m2/2 during
conditioning before i.v. infection with P. falciparum. Data are the mean6SE of n = 21 mice.
doi:10.1371/journal.pone.0002252.g003
P. falciparum in Mice
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infection (R2 = 0.74), with a doubling time of 1.7 days (1.5 to 1.9
days 95% Interval of confidence) (n = 88 mice) (Fig. 5, A)
irrespective of AOB or Rh blood groups. Interestingly,
Pf3D70087/N9 was not strictly dependent on exogenous supple-
mentation of hypoxanthine (parasitemia vs time AUC0R10
17.264.4 days with hypoxanthine vs 12.165.1 days without
hypoxanthine, n = 3 mice?group21, P= 0.15, Student’s t-test).
However, human serum deprivation impaired chimerism (chime-
rism vs time AUC0R10 = 669.9688.3 days with serum vs
289.76152 days without serum, P= 0.02, Student’s t-test) and
parasitemia (parasitemia vs time AUC0R10 = 12.760.1 days with
serum vs 0.660.9 days without serum, n = 3 mice?group21,
P= 0.002, Student’s t-test).
During the assay period, all the erythrocytic stages of the
parasite, except gametocytes, which P. falciparum 3D7 does not
produce neither spontaneously in vitro nor in myelodepleted HM
[11], were noticeable (Fig. 5, B). Multiparasitized erythrocytes
were rare and productive infections occurred apparently only in
hE (Fig. 5, C), as described in vitro [29]. Parasites grew
asynchronously and sequestration of mature stages was not
apparent in mice. Consistently, we did not see endothelial
inflammation, sequestration, or margination of parasites in brain,
kidney, liver or spleen studied at day 8 after infection. In addition,
we did not find intravascular hemolysis, intravascular coagulation
or major histopathological changes in those organs. However,
infection of HM with Pf3D70087/N9 decreased vascular congestion
and increased the number of leukocytes in the spleen (Fig. 3, B).
Next, we set up a standard assay of efficacy (Materials and
Methods) and validated the assay using three established
antimalarials: chloroquine, pyrimethamine and artesunate. These
antimalarials were active in vitro against P. falciparum 3D7 and the in
vivo strain Pf3D70087/N9 (see Table 1). All three compounds were
active when administered orally once a day for 4 consecutive days,
with a clear dose-response effect, (Fig. 6, A). The 95% intervals of
confidence (IC 95%) for the 90% effective dose (ED90) of these
antimalarials were 2.5–6.3, 0.5–1.3, and 10.2–15.2 mg?Kg21, for
chloroquine, pyrimethamine and artesunate, respectively. Only
with dosages that engendered quantitative antiparasitic effects,
circulating parasites showed characteristic structural alterations
(Fig. 6, B–E). Interestingly, after treatment with chloroquine,
recrudescence curves seemed to show a dose-effect relationship
(Fig. 6, F). We also compared the efficacy and pharmacokinetics of
chloroquine in a standard murine model (P. yoelii infection in CD1
mice) and the P. falciparum model. The exposure of chloroquine in
whole blood of non-infected controls or P. yoelii-infected CD1 mice
was 4–5 times higher than in uninfected or infected humanized
NODscid/b2m2/2 mice (Fig. 6, G). However, the pharmacokinetic
profiles were identical in both murine systems. Of note, infection
increased the levels of chloroquine detected in blood of infected
mice in both cases. This effect is likely due to accumulation of the
drug in infected erythrocytes [30]. Consistently, the doses required
to achieve equivalent therapeutic efficacy were slightly higher in
the P. falciparum model compared to P. yoelii model (Fig. 6, G).
To further validate the assay, we also tested the diamidine
analogs of pentamidine DB75 and DB289, its orally bioavailable
pro-drug. These are promising antimalarial compounds that have
proved to be effective in patients infected with P. vivax or suffering
acute uncomplicated P. falciparum malaria [31]. Interestingly,
diamidines seem to require parasite-induced permeability path-
ways in infected erythrocytes [32] and might have several
intracellular targets [31]. Pentamidine has been shown to be
almost inactive against P. berghei but very effective against P. vinckei
in vivo [33–35]. Our results indicated that pentamidine
(40 mg?Kg21, u.i.d., s.c.), DB75 (10 mg?Kg21, u.i.d., s.c.) and
DB289 (100 mg?Kg21, u.i.d., p.o.) were inactive against P. berghei
(Fig. 7, A) but showed a marked activity against P. vinckei (Fig. 7,
B). Interestingly, pentamidine (40 mg?Kg21, u.i.d., s.c.), DB75
(10 mg?Kg21, u.i.d., s.c.) and DB289 (100 mg?Kg21, u.i.d, p.o.)
were also effective against P. falciparum in the murine 4-day test
(Fig. 7, C). This indicated that DB289 was metabolized to active
compounds (presumably DB75) in humanized mice because
DB289 is inactive in vitro and depends on hepatic metabolism to
Table 2. Effect of repeated blood injections on clinical parameters of mice1.
Organ weight (grorgan?grbodyweight?100
21) Days of blood injection
0 7 13 21 P2
Liver 3,6761,5 5,360,7 6,060,3 6,661 ,0,001
Kidney 1,160,04 1,260,12 1,0960,1 1,260,14 NS4
Heart 0,560,05 0,560,05 0,460,03 0,560,02 NS
Lung 0,760,05 0,760,1 0,760,1 0,860,1 NS
Spleen 0,260,04 0,360,05 0,460,06 0,460,05 NS
Serum biochemical markers3
ALT IU?L21 33,1065,4 49,10621,2 52,60610,6 63,20611,8 0,24
BUN mg?dL21 21,5061 31,3064,9 34,0062,8 28,3064,4 ,0,001
AST IU?L21 167,80657 161,20629,7 192,20626,4 226,50650,5 0,25
TBIL mg?dL21 0,6060 5,3066,4 1,7060,3 2,8061,2 ,0,001
TP g?dL21 4,9060,2 5,6060,7 5,8060,3 5,4060,5 0,002
1Each experimental group was n = 5.
2Analysis of organ weight was performed using two factor-ANOVA test followed by Bonferroni post test. Differences were considered significant if P,0,05. Values
reported are the probability of the difference in weight with respect to day 0. In italics groups that differed significantly from control at day 0.
3ALT: Alanine aminotransferase; BUN: Blood Urea Nitrogen; AST: Aspartate aminotransferase; TBIL: Total bilirrubine; TP: Total protein. Analysis of biochemical markers in
serum was conducted using a general linear model multivariate contrast of means followed by a bilateral Dunnett’s t test. In italics groups that differed significantly
from control at day 0.
4NS: Not significant.
doi:10.1371/journal.pone.0002252.t002
P. falciparum in Mice
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exert activity in vivo [31]. Consistently, we did not found dramatic
changes in the morphology of P. berghei in blood smears taken from
infected mice 48 h after starting treatment with compounds,
(Fig. 7, D and E). However, the remaining parasites in peripheral
blood of P. vinckei- (Fig. 7, F and G) and P. falciparum-infected mice
(Fig. 7, H and I) were abnormal late trophozoites-early schizonts,
suggesting that the transition to schizont stage might be an
especially sensitive step to diamidines. These results strongly
suggested that there were significant differences between P.
falciparum and P. berghei in their response to diamidine derivatives,
either because of differences in cellular targets and/or the
specificity of the mechanisms of transport of diamidines into hE.
Thus, according to our results, P. vinckei would be a better
surrogate of P. falciparum than P. berghei for testing in vivo diamidine
derivatives. These results suggested that the falciparum murine
model of malaria might be used to select surrogate standard rodent
models that had better correlation with P. falciparum when testing in
vivo new families of compounds.
Discussion
We describe a reproducible murine model of P. falciparum
infection by generating in vivo parasite strains able to grow
reproducibly in HM and demonstrate its value implementing a
tool for drug discovery of new antimalarials.
We succeeded implementing a reproducible infection with P.
falciparum using the in vivo experimental procedure described by
Moore et al [12]. However, these authors failed to establish a
model of infection useful for drug discovery. Several reasons might
explain this discrepancy. First, the selection of the murine
background for initial infections with in vitro-cultured parasites.
In our hands NODscid/b2m2/2 but not NODscid showed productive
infections after i.p. infection with in vitro growing P. falciparum 3D7.
The deficiency in b2-microglobulin impairs NK cell activity [23]
and leads to iron overload in the liver [23,36]. Thus, additional
defects in the innate immune system of NODscid/b2m2/2, likely
related to defective activation of phagocytes, may lower the initial
selective pressure on P. falciparum. Secondly, the daily injection of
human serum and hypoxanthine might facilitate soluble factors
supporting, directly or indirectly, the growth of P. falciparum [16]
and the engraftment of hE in mice [7]. Thirdly, the variants of P.
falciparum that we selected in vivo had to be competent to overcome
the innate immune system of mice whereas the adaptation of the
parasite to mouse serum in vitro did not establish that selection
pressure [12]. Consistently, the in vivo selection passages led to
variants of P. falciparum 3D7 carrying potential rearrangements to
variable molecules encoding antigenic determinants, which is a
well known mechanism to evade the immune system [37]. In fact,
an improved ability to skip phagocytes might explain the lack of
synchronization in vivo of Pf3D70087/N9. Hopefully, using
Pf3D70087/N5, Pf3D70087/N9, PfV1/S0176/N7 and PfV1/S0176/N10
and other strains in development for new drug discovery
programs, we should be able to map the genomic rearrangements
and compare intra- and inter-strain genotypic and phenotypic
changes associated to the process of in vivo selection in HM.
The daily injection of hE caused the substitution of mE by hE
and polycythemia (hematocrit up to 90%) in mice. As the
clearance of erythrocytes in mice seems to be dependent on the
age of erythrocytes and random mechanisms [38], it is likely that
the decrease of mE reflects a non-selective process of clearing
erythrocytes in excess. HM were able to compensate polycythemia
and the erythrocyte concentration was always below 12?109
E?ml21. Likely, the mechanisms of adaptation to polycythemia are
similar to those found in polycythemic transgenic mice overex-
pressing human erythropoietin [39], which include vasodilatation,
higher flexibility and mean corpuscular volume in newly generated
reticulocytes, accelerated aging of erythrocytes and enhanced
phagocytosis. The relevance of polycythemia in the falciparum
murine model remains to be addressed. However, it is conceivable
that the saturation of the homeostatic mechanisms controlling
Figure 4. Infection dynamics in HM infected with Pf3D70087/N9.
Concentration of hE, ihE and mE in peripheral blood of infected mice.
Data are the mean6SE of three mice per data point. The results are
from a representative experiment out of three. (B) Abrogation of
infection-induced elimination of hE by treatment with chloroquine
(10 mg?Kg21) and exponential growth of Pf3D70087/N9 during recru-
descence. Data are the mean concentration6SE of three mice per data
point. The results are from a representative experiment out of two. (C)
The effect of splenectomy on the percentage of hE and parasites in
peripheral blood. The data are the means6SE of n = 6 mice?group21
pooled from two independent experiments.
doi:10.1371/journal.pone.0002252.g004
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erythrocyte numbers may minimize hE rejection and might be
accountable for the high reproducibility of the kinetics of
parasitemia compared to models not showing this characteristic
[8,9,11]. Importantly, despite the high hematocrit achieved in
HM, we have not detected deaths related to toxicity in more than
one thousand mice used in regular efficacy assays. In contrast, the
most recent version of phagocyte-depleted HM reported a 25%
rate of deaths in HM not infected with P. falciparum even though
hematocrit measurements were almost normal (36 to 52%) [11], a
fact that points to toxicity of the phagocyte depletion method.
Parasite density in peripheral blood is a key driver of the model
dynamics. After i.v. infection, Pf3D70087/N9 causes a selective
elimination of hE, but as long as the parasite density is below a
threshold, it does not alter significantly the dynamics of the system
and Pf3D70087/N9 grows exponentially. Noteworthy, the selective
clearance of uninfected hE might have some clinical relevance
because anemia is the most frequent clinical complication of
falciparum malaria [40] and P. falciparum-induced elimination of hE
is a key factor in its pathogenesis [41,42]. Infection-induced
membrane rigidification [43] and selective tagging with merozoite
RSP-2 rhoptry protein of hE [44] have been proposed as relevant
mechanisms, and could be involved in our model as well. In
agreement with previous reports [8,9,11], our results suggest that
the recruitment and activation of phagocytes have a central role
limiting the growth of P. falciparum in HM. Thus, we anticipate
that the overall dynamics of the system described in this paper can
be manipulated by deleting in vivo activation and/or homing
receptors of phagocytes. Moreover, it is important to note that this
dynamic of infection differs substantially from the model proposed
by Moreno et al. in phagocyte-depleted HM after intraperitoneal
infection [26]. In this model, only depletion of phagocytes would
allow the intraperitoneal growth of P. falciparum. Ultimately, the
intraperitoneal infection of phagocyte-depleted HM with P.
falciparum would lead to spontaneous parasite clearance or mouse
death depending on the capacity of surviving peritoneal
phagocytes to control parasite replication in the peritoneum.
Consistently, no successful intravenous infection have been
described in phagocyte-depleted HM models.
Willimann et al. [45] showed that P. falciparum ItG2.F6-infected
erythrocytes injected in scid mice bind selectively in vivo to ICAM-
1-positive murine endothelium. Whether this phenomenon takes
place in HM infected with P. falciparum remains to be addressed.
However, we found all stages of the parasite (except gametocytes)
circulating in peripheral blood, without microscopic evidence of
attachment or manifest clinical symptoms in HM. Thus, our
results suggested that there was no prominent adhesion of the
strains generated in HM to murine endothelium in vivo. The in vivo
selection procedure employed to generate P. falciparum strains
might favor the expansion of parasites with reduced ability to bind
murine endothelium. However, it is important to note that
Moreno et al. [11] did not find margination in phagocyte-depleted
HM infected with P. falciparum even though no previous selection
or adaptation of the parasite was employed. In any case, the lack
of adhesion was an advantage for the evaluation of antimalarial
drugs since the effect of the drugs on all stages is readily observable
and the evaluation of the dose/exposure-response relationships is
easier and technically more accurate. Conversely, this may be the
most important limitation of the falciparum model described here
for pathology or cytoadhesion studies. It is interesting to note that
Moore et al [12] found that P. falciparum 3D7 adapted in vitro to
murine ascites could differentiate to gametocytes upon infection of
HM. This is in contrast with the results reported in this paper
using Pf3D70087/N9 and by Moreno et al. [11] in phagocyte-
depleted HM using P. falciparum 3D7. As the three approaches
have substantial differences, there are no obvious explanations for
this discrepancy. P. falciparum 3D7 does not produce spontaneously
gametocytes in vitro. Thus, it would be likely necessary to test other
strains, particularly clinical isolates, in the in vivo selection
procedure in HM to assess the capacity of the falciparum HM to
allow the differentiation to gametocytes, a trait already proven for
Table 3. Dynamics of infection in HM1.
Days after
infection % hE % Parasitemia2 Parasites?ml21 (6106) E?ml21 (6106) hE?ml21 (6106) mE?ml21 (6106)
1 59,761,5 0,160 15,162,1 10384,96125 6193,56110,1 4191,36201
3 66,760,6 0,760,1 73,7612,3 10643,9620,1 7102,7656,8 3541,1665,5
6 68,561,5 2,160,1 156,2612,3 7370,96193,4 5050,76152,3 2320,26141,1
8 73,761,6 3,160,6 215,8641,5 68756502,4 5071,36465,7 1803,7677,7
10 79,761 4,960,8 299,9637,1 6222,86394,8 4962,66368,2 1260,2643,7
13 73,264,9 5,661,2 270,9663 4821,46351,1 3540,56431,1 1280,96189,8
15 62,567,8 5,661,1 278,5673,3 4953,46296,2 3112,36531,9 1841,16314,2
17 48,167,3 4,960,5 263,7618,8 5370,36590,4 2538,16143,3 2832,26731,1
20 13,3614,6 1,361,5 836101,8 5549,76698,3 839,46969,1 4710,46275,7
21 15,6610,5 0,961,3 57,3680,5 5933,96330,4 940,96667,1 49936563,6
23 28,667,3 0,861,2 53,2673,4 7544,86909,1 2115,26460,5 5429,561101,4
27 46,4616,6 0,160,1 11,868,5 8673,26950,9 4178,261774,4 44956826,4
29 54,1611 0,360,3 27,5623,3 8933,46625,6 4905,661283,8 4027,86658,9
31 59,3610,1 0,960,8 67,9660,6 8646,66789,2 5116,26983,2 3530,461018,5
34 62,369,3 2,162,2 139,26135,6 7216,26607,3 4519,96948,8 2696,36630,2
36 67,9610,5 2,661,3 180,5682,2 7815,261751,3 5454,561961,1 2360,76605,4
1Data are the mean6SEM of n = 3 mice infected at day 0 with 20?106 Pf3D70087/N9-parasitized erythrocytes/mouse obtained from peripheral blood of a donor mouse.
2Total parasitemia.
doi:10.1371/journal.pone.0002252.t003
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phagocyte-depleted HM [11]. In any case, it is unlikely that any
falciparum murine model can reflect all the pathophysiological
characteristics of human falciparum malaria. Thus, devising
specialized falciparum murine models that modeled reproducibly
key aspect of the parasite’s biology in humans might be a more
realistic approach.
Discovery of new antimalarial drugs is a priority for global
health programs. With the exception of humans, the murine
falciparum models are the only ones that enable the evaluation of
antimalarial drugs against P. falciparum inside human erythrocytes
in vivo. Thus, they may be unique tools to study the effect of drug
exposure in blood on parasitemia. Moreno et al. [9], using the
sensitive strain NF54 and the chloroquine/quinine resistant T24
strain of P. falciparum demonstrated that using phagocyte-depleted
HM having at least 6 days of stable parasitemia it was possible to
detect active compounds against P. falciparum. However they did
not show whether their experimental design could address dose-
response relationship for any of the standard antimalarials used
[9]. To the best of our knowledge, our paper describes the first
assay in which a dose-response relationship for antimalarials has
been reported in an antimalarial assay set up using a falciparum
murine model. Thus, our model enabled us to compare the
relative potency of compounds in vivo, assessing the actual blood
exposures of each compound with its therapeutic efficacy in the
Figure 5. Characterization of the P. falciparum-malaria model for antimalarial drug testing. (A) Kinetics of parasitemia in peripheral blood
of HM infected i.v. with 20?106 Pf3D70087/N9 parasites. Data are the mean6SE from 88 mice. The inset plot shows the regression line to fit an
exponential growth model of the means of parasitemia of the pooled data up to day 7 after infection. (B) Giemsa-stained smears from peripheral
blood of HM infected i.v. with Pf3D70087/N9 showing the different stages of P. falciparum: ring (upper row on the left) to mature schizont (lower row
on the right) (61000 magnification). (C) Replication of Pf3D70087/N9 in hE. Flow cytometry panels depict erythrocyte populations in control (left panel),
uninfected HM (middle panel) and infected HM (right panel). The percentage of mE TER-119+ cells is indicated. Pf3D70087/N9 (parasitemia 6%) are in
TER-1192SYTO-16+ events. Pycnotic forms of P. falciparum were found in Giemsa stained-cytospin preparations of mE TER-119+ purified
immunomagnetically. Viable parasites were found in purified hE TER-1192. Data are representative of three independent experiments. (D) Q–Q plot
of normality for the variable log10 (parasitemia at day 7) showing observed values vs expected normal values (n = 327 mice).
doi:10.1371/journal.pone.0002252.g005
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Figure 6. Validation of the P. falciparum 4-day test. (A) Therapeutic efficacy of chloroquine, artesunate, and pyrimethamine using the standard
P. falciparum 4-day test. Data are the mean parasitemia6SE of n = 3 mice?group21 from a single experiment using 45 mice. (B, C, D, E) Representative
blood smears 48 h after starting treatment with saline, chloroquine (20 mg?Kg21), artesunate (25 mg?Kg21) or pyrimethamine (20 mg?Kg21),
respectively. The remaining parasites in peripheral blood after treatment with chloroquine or artesunate were pycnotic cells and disrupted
trophozoites. Pyrimethamine led to swollen late trophozoites with prominent granules of hemozoin (61000 magnification). (F) Logarithmic growth of
Pf3D70087/N9 during recrudescence after treatment with chloroquine (10 and 20 mg?Kg21, p.o., u.i.d.) in a standard 4-day test. Data are the mean
parasitemia6SE of three mice/group. (G) Exposure-therapeutic efficacy relationships of chloroquine in the P. yoelii or the P. falciparum murine models
of malaria. Data are the mean concentration of chloroquine in blood of n = 3 mice?group21.
doi:10.1371/journal.pone.0002252.g006
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same animal species, using a highly reproducible standardized
assay, and avoiding potentially interfering toxic reagents. Indeed,
the antimalarial assay described has been used to support the lead
optimization of a number of antimalarial projects funded by
Medicines for Malaria Venture, including 4-(1)-pyridones, falci-
pain inhibitors, dihydrofolate reductase inhibitors, and diamidine
derivatives (manuscript in preparation). It is worth mentioning that
the actual exposures in blood of several compounds tested were
lower in HM than in normal CD1 mice in all the cases studied.
Likely, an increase in vascular volume due to vasodilatation
contributed to lower exposures. However, changes in absorption
and metabolism might play an important role, either increasing or
decreasing the actual blood exposures of new families of
compounds. Considering its use in drug discovery, the model
described in this paper is especially well suited to evaluate
compounds inhibiting P. falciparum-specific targets at any stage of
the drug discovery process. However, it is more expensive than the
standard rodent models of malaria, which are reliable, reproduc-
ible and affordable. Hence, it seems logical that these standard
models should be the first choice for preliminary experiments of
therapeutic efficacy if they proved to be good surrogates of P.
falciparum. To test this point, the falciparum model described in this
paper might provide a reference to select appropriate rodent
plasmodial species to test in vivo new families of antimalarials, and,
given their urgent need, to re-evaluate promising compounds
active in vitro against P. falciparum that were discarded because they
failed in vivo against rodent Plasmodium spp.
In this paper, we demonstrate that it is possible to generate in
vivo strains of P. falciparum competent to grow reproducibly in
peripheral blood of HM without using toxic treatments to deplete
phagocytes. These parasite strains are tools that may be as useful
in malaria as the strains adapted to in vitro culture, currently the
Figure 7. Therapeutic efficacy of diamidine derivatives against P. berghei, P. vinckei and P. falciparum. (A, B, C) Therapeutic efficacy of
pentamidine (40 mg?Kg21, u.i.d., s.c.), DB75 (10 mg?Kg21, u.i.d., s.c.) or DB289 (100 mg?Kg-1, u.i.d., p.o.) against P. berghei, P. vinckei and P. falciparum,
respectively. We started treatment when parasitemias where comparable and administered compounds for 4 days. (D, E) Giemsa-stained blood
smears from mice infected with P. berghei obtained 48 h after starting treatment with vehicle or DB75 at 10 mg?Kg21, respectively (61000
magnification). Neither relevant cellular damage nor significant inhibition of parasitemia were observed at the time of sampling. (F, G) Giemsa-stained
blood smears from mice infected with P. vinckei obtained 48 h after starting treatment with vehicle or DB75 at 10 mg?Kg21, respectively (61000
magnification). Parasites from treated mice were mostly abnormal late trophozoites. (H, I) Giemsa-stained blood smears from mice infected with P.
falciparum obtained 48 h after starting treatment with vehicle or DB75 at 10 mg?Kg21, respectively (61000 magnification). Parasites from treated
mice were mostly abnormal late trophozoites.
doi:10.1371/journal.pone.0002252.g007
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cornerstone of research in P. falciparum. As the use of competent
strains guarantees a reliable growth of the parasite in HM, it
should be possible to devise new falciparum murine models using
humanized immunodeficient mice with specific defects in
phagocyte activity/activation and expressing human adhesion
molecules in endothelium. These tools will hopefully open up
more ways to study the biology of the erythrocytic stages of P.
falciparum in vivo and its molecular responses to selective pressures
imposed by antimalarials or the human immune system reconsti-
tuted in mice [26,46,47].
Materials and Methods
Compounds
Chloroquine, artesunate, artemisinin, pentamidine and pyri-
methamine were purchased from Sigma (St. Louis, MO).
Atovaquone is owned by GlaxoSmithKline. DB75 and DB289
were obtained from Medicines for Malaria Venture. Chloroquine
diphosphate was dissolved in saline. Artesunate (AAPIN Chem-
icals Ltd., Abingdon, UK) was prepared as suspensions in water
1% hydroxipropil-b-cyclodextrine (FLUKA, Seelze, Germany).
Pyrimethamine was prepared as suspensions in water 1%
methylcellulose (Sigma). Pentamidine, DB75 and DB289 were
dissolved in 70% Tween 80 and 30% ethanol and then further
diluted 1/10 with distilled water. All compounds were dissolved in
RPMI 1640 human serum 10% DMSO 0.2% for in vitro testing.
Parasites
Drs. E. Dei-Cas and L. Delhaes from Institut Pasteur (Lille,
France) kindly donated uncloned P. falciparum 3D7, Plasmodium
berghei and Plasmodium yoelii 17 X. Both Plasmodium falciparum V1/S
and Plasmodium vinckei were obtained from the Malaria Research
and Reference Reagent Resource Center (ATCC, Manassas, VA,
USA). Parasites were cryopreserved and thawed using the
glycerol/sorbitol method with minor modifications [48,49].
Mice
Female CB17scid (CB17/Icr.Cg-Prkdcscid), CB17scid/beige (CB17/
Icr.Cg-Prkdcscid Lystbg/Crl), NIH-IIIbeige/xid/nude (Crl:NIH-Lystbg
Foxn1nu Prkdcxid), NODscid/b2m2/2 (NOD.Cg-PrkdcscidB2mtm1Unc/J)
and NODscid (NOD.CB17-Prkdcscid/J) were purchased from The
Jackson Laboratory (Bar Harbor, ME). A colony of NODscid/b2m2/2
mice was raised and maintained by Charles River Laboratories
(L’Arbresle, France). The mice were used at 8 weeks of age. The
mice were fed with autoclaved tap water and c-irradiated pelleted
diet ad libitum. All the experiments were approved by DDW-Ethical
Committee on Animal Research and were conducted according to
European Union legislation and GlaxoSmithKline policy on the care
and use of animals.
Blood
We employed incomplete donations or erythrocyte concentrates
of malaria-negative donors, generously provided by the Spanish
Red Cross blood bank in Madrid, Spain. Before injection, blood
stored at 4uC was washed twice with RPMI 1640, 25 mM HEPES
(Sigma) containing 7?1023 mM hypoxanthine (Sigma) at room
temperature. The buffy coat was removed by aspiration (if
required) and erythrocytes resuspended at 50% hematocrit in
RPMI 1640, 25% decomplemented human serum (Sigma)
3.1 mM hypoxanthine. Finally, the blood suspension was warmed
at 37uC for 20 minutes before intraperitoneal injection with 1 ml
of hE suspension every day during the experiments.
In vitro cultures
Asexual stage P. falciparum 3D7 parasites were maintained in
continuous culture as described [50] with minor modifications.
Growth inhibition assays were assessed by monitoring [3H]-
hypoxanthine uptake as described previously [51]. Inhibitory
concentrations at 50 and 90% (IC50 and IC90, respectively) were
determined by fitting a sigmoid dose-response curve to experi-
mental data using GraphPad Prism 4.0 (GraphPad Software, San
Diego, CA).
Parasite typing
Polymorphic microsatellite fingerprinting of Plasmodium falci-
parum within a multicopy rif repetitive element [52] (PfRRM) was
carried out following the method published by Su et al. [27] with
minimal modifications. Genomic DNA was PCR amplified using
the described primers set (Fwd TACGTTACATTATGTTTTA
labeled with 6-FAM and Rev ATATGTATTGCGCTTTTA).
The size of the amplicons was analyzed in an automated single-
capillary genetic analyzer Abi Prism 310 Genetic Analyzer (GMI,
Inc., Ramsey, MN).
Histology
Female NODscid/b2m2/2 mice were injected daily with 1 ml of
hE for 10 days and infected or not (conditioned controls) with
20?106 P. falciparum-infected erythrocytes. Brain, lungs, kidneys,
liver and spleen from all experimental groups were aseptically
removed at day 8 after infection and fixed in toto by immersion in
neutral buffered 10% formalin solution for 48 h. Serial cross
sections of the organs were obtained and fixed again in formalin
for 12 h. Finally, tissue sections were embedded in paraffin, 5 mm
thick sections were prepared and these were stained with
hematoxylin and eosin and examined. Blood smears for assessing
parasites were performed as described [53].
Flow cytometry
All mAb were from BD Biosciences Pharmingen (San Diego,
CA). We measured the expression of murine myeloid markers Ly-
6G and F/480 in leukocytes exactly as described [54]. Measure-
ment of parasitemia in peripheral blood was assessed by measuring
the percentage of hE containing nucleic acids. Blood samples were
taken from the tail lateral vein (2 mL), collected onto 100 mL of
saline containing 10 mg ml21 PE-conjugated rat IgG2b anti-
mouse erythrocyte TER-119 mAb [55], incubated for 20 min,
fixed with glutaraldehyde and stained with YOYO-1 (Molecular
Probes, Leiden, The Netherlands) as described previously [56].
Engraftment with hE was routinely measured as the percentage of
TER-1192 erythrocytes, which rendered the same results obtained
by measuring glutaraldehyde-fixed erythrocytes with PE-conju-
gated rat anti-human glycophorin A mAb. For measurement of
the concentration of cells in blood, 2 mL of blood were obtained
from the tail lateral vein, collected onto 100 mL of staining solution
(SYTO-16 (Molecular Probes) at 5 mM [57,58] and 10 mg ml21
PE conjugated anti-mouse TER-119 monoclonal antibody [55]) in
96-well V-bottomed plates, incubated for 20 minutes at room
temperature and neutralized for 10 minutes with 10 mL of 0.25%
glutaraldehyde per well. For acquisition, 30 mL of the sample were
added to TruCountsTM tubes (Becton Dickinson) [59] containing a
known number of lyophilized fluorescent beads suspended in
300 mL of saline. The sensitivity to detect infected erythrocytes
was 0.01% and measurements were linear across the range of
sensitivity. Either YOYO-1 or SYTO-16 were used because they
showed no significant differences for parasitemia determinations
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(Pearson’s coefficient of correlation r = 0.998) (Jime´nez-Dı´az et al.,
submitted).
Magnetic sorting of erythrocytes
Purification of TER-119+ erythrocytes was performed exactly as
described previously [56]. Briefly, 10 mL of blood were washed
with PBS, resuspended in 0.25 ml of PBS 1% FCS (Sigma) and
stained with biotinylated rat anti-mouse TER-119 (BD Biosciences
Pharmingen) at 10 mg ml21 for 30 min at room temperature.
After washing twice with separation buffer (PBS 0.5% BSA 2 mM
EDTA), the cells were resuspended in 0.45 ml of this buffer plus
50 mL of streptavidin conjugated BD iMag DM particles (BD
Biosciences Pharmingen) and incubated for 30 min at 4uC.
Finally, 0.55 ml of separation buffer was added to the sample
and the cellular suspension was exposed to DYNAL MPC-1
Magnetic Particle Concentrator (Dynal, Oslo, Norway) for 6 min.
Negative and positive fractions were carefully collected and
subjected to another cycle of purification. The quality of
purification was assessed by flow cytometry as described [56].
Evaluation of in vivo antimalarial therapeutic efficacy
We measured the efficacy of antimalarial compounds against P.
yoelii or P. berghei in a ‘4-day test’ [60] as described previously [56].
We adapted this assay to measure the therapeutic efficacy against
P. falciparum. Cohorts of age matched female (40 to 80, depending
on the experiment) NODscid/b2m2/2 were injected i.p. daily with
hE throughout the experiment. When the mice reached $40% of
chimerism in peripheral blood (7–9 days after initiation of
injections), we infected them i.v. with 20?106 parasites obtained
from infected donors and the mice were randomly distributed in
groups of n = 3 mice?group21 (day 0). Treatments were admin-
istered from day 3 until day 6 after infection. We measured the
percentage of TER-1192YOYO-1+ (or SYTO-16+) hE in
peripheral blood at day 7 after infection and recrudescence up
to day 35 if the parasitemias were below our detection limit
(0.01%). We determined the minimum size of each experimental
group (n = 3) to detect a reduction of 50% in parasitemia in
peripheral blood assuming Type I error a= 0.05 (confidence level)
and Type II error b= 0.2 (power of the assay). This sample size
was calculated upon the distribution of the decimal logarithm of
the mean percentage of TER-1192YOYO-1+ parasitized hE,
which is normally distributed (log parasitemia 0.33460.01;
n = 327 mice, P.0.2, Kolmogorov–Smirnov test of normality
with Lilliefors’ correction of significance) (Fig. 5D). The therapeu-
tic efficacy of compounds was expressed as the effective dose
(mg?Kg bodyweight
21) that reduces parasitemia by 90% with respect
to vehicle treated groups (ED90). All compounds and correspond-
ing vehicles were administered orally at 20 ml?Kg21 or subcuta-
neously at 10 ml?Kg21, as appropriate. Chloroquine is included as
quality control for each in vivo assay.
In vivo pharmacokinetic studies in mice
Experimental mice (n = 3 mice?group21) received a single bolus
dose of chloroquine (10 mg?Kg21, p.o. in sterile saline). Blood
samples (25 ml) were collected by puncture of the lateral tail vein,
mixed 1:1 with de-ionized water 0.1% saponin and stored frozen
at 270uC until use. After protein precipitation and liquid/liquid
extraction, the samples were assayed by LC/MS using ESI in Q1
M+1 mode conditions by selected ion monitoring in an API 2000
mass spectrometer (Applied Biosystems Sciex, Foster City, CA)
coupled to a HPLC chromatograph (Agilent HP1100 Series,
Agilent Technologies Spain). Quantification was conducted by
comparison to calibration curves. Blood concentrations versus time
data were analyzed by non-compartmental analysis (NCA)
methods using WinNonlinH Professional Version 4.1 (Pharsight
Corporation, Mountain View, CA) and GraphPad Prism 4.0
(GraphPad Software).
Clinical evaluation of mice
The clinical evaluation of mice was performed through a
functional observational battery in order to assess behavior and
nervous system responses [61]. Blood samples were taken in
heparin-Litium tubes (Sarstedt, Nu¨mbrecht, Germany), centri-
fuged at 1500 g for 10 minutes and plasma was separated to be
analyzed in a Beckman CX5 biochemical autoanalyzer (Beckman
Coulter, Fullerton, CA). Hematology analyses were performed
using a Coulter AcT.5.Diff (Beckman Coulter).
Statistics
Observational studies were performed with pooled data from
mice used in routine standard in vivo assays of new antimalarials.
Sample sizes for comparative experiments were calculated to
detect a decrease of 50% in the mean of control group for Type I
error a= 0.05 and 80% of power, unless otherwise stated. For
comparison of kinetic curves we assessed the area under the curve
(AUC) instead of comparing individual data points that do not
account for the temporal dimension of data [62].The variables
percentage of chimerism in peripheral blood of mice and
percentage of parasitemia vs time AUC0Rt were normally
distributed. Comparison of the mean of each experimental group
was analyzed by Student’s t test, one factor ANOVA followed by
Dunnett’s, Tukey’s HSD or Games-Howell post tests, two factor
ANOVA followed by Bonferroni post-test or Multivariate General
Linear Model followed by a Dunnett’s post test, as appropriate.
Homogeneity of variances was assessed by Levene’s test. Data
variability is expressed as standard error (SE) throughout the
paper. Analysis was performed using SPSS 13.0 for Windows
(SPSS Inc., Chicago, IL). Probability values larger than 0.05 were
considered not significant.
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